Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Nasdaq Real Time Price USD

Baird Medical Investment Holdings Limited (BDMD)

Compare
5.50
-0.14
(-2.48%)
At close: 4:00:00 PM EDT
5.47
+0.01
+(0.18%)
After hours: 4:05:06 PM EDT
Loading Chart for BDMD
  • Previous Close 5.64
  • Open 5.47
  • Bid 5.19 x 100
  • Ask 9.00 x 100
  • Day's Range 5.44 - 5.98
  • 52 Week Range 1.05 - 13.52
  • Volume 20,187
  • Avg. Volume 566,498
  • Market Cap (intraday) 199.992M
  • Beta (5Y Monthly) -0.59
  • PE Ratio (TTM) 15.71
  • EPS (TTM) 0.35
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China and the United States. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.

www.bairdmed.com

148

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BDMD

View More

Performance Overview: BDMD

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BDMD
27.63%
S&P 500 (^GSPC)
3.58%

1-Year Return

BDMD
49.77%
S&P 500 (^GSPC)
8.94%

3-Year Return

BDMD
44.83%
S&P 500 (^GSPC)
24.75%

5-Year Return

BDMD
44.16%
S&P 500 (^GSPC)
124.42%

Compare To: BDMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDMD

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    203.99M

  • Enterprise Value

    218.01M

  • Trailing P/E

    15.85

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.02

  • Price/Book (mrq)

    5.20

  • Enterprise Value/Revenue

    6.60

  • Enterprise Value/EBITDA

    13.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    37.96%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    33.05M

  • Net Income Avi to Common (ttm)

    12.55M

  • Diluted EPS (ttm)

    0.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.66M

  • Total Debt/Equity (mrq)

    39.53%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BDMD

View More

Company Insights: BDMD

Research Reports: BDMD

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.